These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 6285119)

  • 21. Inoculum size effect on the MIC of cefoperazone, moxalactam, cefotaxime, cefoxitin and cephalothin for 118 strains of Haemophilus influenzae including 'tolerant' micro-organisms.
    Simard P; Bergeron MG
    J Antimicrob Chemother; 1982 Nov; 10(5):397-402. PubMed ID: 6294044
    [No Abstract]   [Full Text] [Related]  

  • 22. [Antibacterial activities of new cephems against clinically isolated organisms (author's transl)].
    Okada K; Kawamura N; Ohkoshi M; Satake Y; Kawakita J
    Jpn J Antibiot; 1982 Apr; 35(4):1009-21. PubMed ID: 6285019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.
    Mintz L; Drew WL
    Antimicrob Agents Chemother; 1981 Feb; 19(2):332-4. PubMed ID: 6289731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Moxalactam: preclinical evaluation].
    Chabbert YA
    Sem Hop; 1983 Jun; 59(26):1943-6. PubMed ID: 6310782
    [No Abstract]   [Full Text] [Related]  

  • 25. Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins.
    Khan NJ; Bihl JA; Schell RF; LeFrock JL; Weber SJ
    Antimicrob Agents Chemother; 1984 Oct; 26(4):585-90. PubMed ID: 6549120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative activity of N-formimidoyl thienamycin with third generation cephalosporins and ureido penicillins against multiple resistant Serratia marcescens.
    Miller MA; LeFrock JL; Vercler MJ
    Microbiol Immunol; 1981; 25(11):1119-27. PubMed ID: 6276701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in-vitro activity of moxalactam and cefotaxime against isolates from blood culture.
    Ramirez-Ronda CH; Nevarez M; Saavedra S; Bermudez RH
    J Antimicrob Chemother; 1981 Jun; 7(6):629-35. PubMed ID: 6265427
    [No Abstract]   [Full Text] [Related]  

  • 28. The activity of five cephalosporins against Bacteroides fragilis.
    Ryan RW; Kwasnik I; Tilton RC
    Ann Clin Lab Sci; 1982; 12(1):32-4. PubMed ID: 6279014
    [No Abstract]   [Full Text] [Related]  

  • 29. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.
    Jorgensen JH; Crawford SA; Alexander GA
    Antimicrob Agents Chemother; 1980 Jun; 17(6):937-42. PubMed ID: 6250470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro antimicrobial activity of ceftizoxime.
    Schell RF; LeFrock JL; Smith BR; Francisco M
    Chemotherapy; 1983; 29(6):408-14. PubMed ID: 6317295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of the in vitro activity of new cephalosporins on strains of Neisseria gonorrhoeae of the Toulouse region.
    Prère MF; Lefèvre JC; Lareng MB
    Chemotherapy; 1981; 27 Suppl 1():15-8. PubMed ID: 6265158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Hanslo D; King A; Shannon K; Warren C; Phillips I
    J Antimicrob Chemother; 1981 Jun; 7(6):607-17. PubMed ID: 6265426
    [No Abstract]   [Full Text] [Related]  

  • 33. Antibacteroides and beta-lactamase inhibitory activities of moxalactam.
    Fu KP; Neu HC
    J Antimicrob Chemother; 1981 Oct; 8(4):337-41. PubMed ID: 6271727
    [No Abstract]   [Full Text] [Related]  

  • 34. In vitro activity of ceftazidime and ceftriaxone.
    Keenholtz SL; Jacobus NV; Tally FP; Gorbach SL
    Clin Ther; 1983; 5(6):603-16. PubMed ID: 6313195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.
    Shelton S; Nelson JD; McCracken GH
    Antimicrob Agents Chemother; 1980 Sep; 18(3):476-9. PubMed ID: 6252837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The comparative activities of N-formimidoyl theinamycin (MK0787), moxalactam, cefotaxime and cefoperazone against Yersinia enterocolitica and Listeria monocytogenes.
    Ahonkhai VI; Sierra MF; Cherubin CE; Shulman MA
    J Antimicrob Chemother; 1982 May; 9(5):411-2. PubMed ID: 6284696
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro evaluation of LY127935 (6050S) compared with cefotaxime, eight other beta-lactams and two aminoglycosides.
    Barry AL; Thornsberry C; Jones RN
    J Antimicrob Chemother; 1980 Nov; 6(6):775-84. PubMed ID: 6254942
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.
    Jorgensen JH; Crawford SA; Alexander GA
    Antimicrob Agents Chemother; 1980 May; 17(5):901-4. PubMed ID: 6249198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis.
    McCracken GH; Nelson JD; Grimm L
    Antimicrob Agents Chemother; 1982 Feb; 21(2):262-7. PubMed ID: 6280599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility of gram-positive cocci to various antibiotics, including cefotaxime, moxalactam, and N-formimidoyl thienamycin.
    Cherubin CE; Corrado ML; Sierra MF; Gombert ME; Shulman M
    Antimicrob Agents Chemother; 1981 Oct; 20(4):553-5. PubMed ID: 6282200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.